MedElevator Войти в исследования
← Поиск публикаций

DOI 10.6004/jnccn.2025.7048

Медицинская библиотека · Journal of the National Comprehensive Cancer Network : JNCCN · 2025

Sarcopenia, Elevated Body Mass Index, and Platinum-Associated Adverse Events in Patients With Lung Cancer.

Lyu Jiaxuan, Mantz Lea, Katz-Agranov Nurit S, Ouyang Tianqi, Hanna Paul E, Mejia Sherley M, Moreno Daiana, Lee Meghan, Cao Andrew, Dinulos James E, Cosar Duru, Shaker Michel, Shah Sachin J, Gainor Justin F, Temel Jennifer S, Lei Matthew, Inker Lesley A, Fintelmann Florian J, Sise Meghan E

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Patients with sarcopenia and elevated body mass index (BMI) are at high risk of platinum-associated adverse events (AEs). This study examines the association between sarcopenia, BMI, and AEs in patients with non-small cell lung cancer (NSCLC).

METHODS

This retrospective cohort study included adult patients with NSCLC who started cisplatin or carboplatin between 2015 and 2022. Sarcopenia was defined on CT using sex-specific cutoffs for skeletal muscle index. We evaluated the association between CT-defined sarcopenia and grade ≥2 AEs (including anemia, thrombocytopenia, neutropenia, and increased creatinine), chemotherapy discontinuation, and 90-day mortality in patients with normal (<25 kg/m2) and elevated (≥25 kg/m2) BMI using a Fine-Gray subdistribution hazard model. The association between receiving an excess carboplatin dose and AEs was evaluated.

RESULTS

Of 604 included patients, the mean [SD] age was 66 [10] years, 307 (51%) were female, and 167 (28%) had sarcopenia. Sarcopenia and elevated BMI (n=67) was associated with an increased risk of grade ≥2 anemia (subdistribution hazard ratio [sHR], 1.64; 95% CI, 1.17-2.29; P=.004), thrombocytopenia (sHR, 2.25; 95% CI, 1.16-4.36; P=.016), and increased creatinine (sHR, 2.72; 95% CI, 1.45-5.13; P=.002). Sensitivity analyses demonstrated that patients whose Cockcroft-Gault-based glomerular filtration rate (GFR) dictated a carboplatin dose ≥25 mg higher than CKD-EPI GFR were at significantly higher risk of grade ≥2 AEs and chemotherapy discontinuation.

CONCLUSIONS

Combined CT-defined sarcopenia with elevated BMI is associated with an increased risk of platinum-associated AEs in patients with NSCLC; this may be due to GFR misestimation in patients with low muscle mass and elevated BMI.

Для цитирования: Lyu Jiaxuan, Mantz Lea, Katz-Agranov Nurit S, Ouyang Tianqi, Hanna Paul E, Mejia Sherley M, Moreno Daiana, Lee Meghan, Cao Andrew, Dinulos James E, Cosar Duru, Shaker Michel, Shah Sachin J, Gainor Justin F, Temel Jennifer S, Lei Matthew, Inker Lesley A, Fintelmann Florian J, Sise Meghan E. Sarcopenia, Elevated Body Mass Index, and Platinum-Associated Adverse Events in Patients With Lung Cancer.. Journal of the National Comprehensive Cancer Network : JNCCN. 2025. DOI: 10.6004/jnccn.2025.7048.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.